Clipping of news on Brazilian Culture, Law and Citizenship
08/30/2012
This article was translated by an automatic translation system, and was therefore not reviewed by people.
Called Stribild, drug provides full treatment to combat the disease
A new once-daily pill to fight AIDS - which combines two drugs already authorized - was approved for adults with HIV, said on Monday the drug regulatory agency of the United States (FDA).
Called Stribild, this daily single tablet provides a complete treatment against AIDS and is part of increasingly simple options against HIV, said the Food and Drug Administration (FDA acronym in English).
"Through continued research and development of medicines, treatment for those infected with HIV has evolved multiple pills just one pill" daily, said Edward Cox, director of the Bureau of Antimicrobial Products in the FDA's drug evaluation.
"New drug combinations for HIV, as Stribild will help simplify the treatments."
The new drug, manufactured by Gilead Sciences California (west) was tested in more than 1400 patients in two clinical trials and the results showed that the Stribild is as effective or more than two other combinations of treatments, reducing HIV to undetectable levels nine out of ten patients after 48 weeks of ingestion.
Stribild combines Truvada - emtricitabine and tenofovir against an enzyme that HIV uses to reproduce - to elvitegravir, another substance that fights an enzyme associated with cobicistat, which potentiates the effects of elvitegravir.
The drug was tested in previously untreated adult patients with AIDS. The FDA said it will take further study to determine the safety of children and women and have no interaction with other substances.
Stribil has some side effects, including liver problems and kidney, accumulation of lactic acid in the blood and weakening of the bones, but Gilead claims that during tests "most adverse events were mild or moderate."
The drug causes nausea and diarrhea among patients.
"The therapies that meet the individual needs of patients are essential to improve maintenance of treatment and its potential for success," said the chairman of Gilead, John Martin.
To get the drug to patients with HIV in countries with fewer resources, where millions of people have no effective treatment options are being developed with the generic approval and help of Gilead, in partnership with several Indian companies and the Medicines Patent Pool with , a nonprofit organization that promotes the manufacture of generics.
Source: Everyday Health
Our news are removed entirely from the sites of our partners. For this reason, we can not change their content even in cases of typos.
This article was translated by an automatic translation system, and was therefore not reviewed by people.